#sy

  1. So-Young Dolls Up With Pivot To High-End Services

    By The Bamboo Works Key Takeaways: So-Young reported an annual profit last year, reversing two years of losses, as its revenue rose 19% The company’s new So-Young Prime service for high-end users helped to fuel a 22.2% revenue jump in its information services segment last year By Edi
  2. Earnings Scheduled For March 20, 2024

    By Benzinga Insights Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ: TIGR ) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. • Fanhua (NASDAQ: FANH ) is estimated to report earnings for its fourth quarter. • Mogo (NASDAQ: MOGO ) i
  3. Two Cold Weather Payments worth total of £50 now due in certain postcodes as DWP shares full list of triggers

    By Jessica Sheldon More Cold Weather Payments have been triggered in the UK, with some people now due to get £50 so far this winter. There has been a second trigger in one area, with two payments now due in certain postcodes in Cumbria. The weather station used to determine the temp
  4. Earnings Scheduled For November 20, 2023

    By Benzinga Insights Companies Reporting Before The Bell • Greenland Technologies (NASDAQ: GTEC ) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million. • Pyxis Tankers (NASDAQ: PXS ) is estimated to report quarterly earnings at $0.19 per share on rev
  5. Yonghe Medical's Share Repurchase Gets Results, But Can't Hide A Receding Profit Line

    By The Bamboo Works Key Takeaways: Yonghe Medical’s gamble on growing demand for its hair transplant services led to losses in the second half of 2022 and first six months of 2023 A stock repurchase plan announced late last month propped up its shares, but the stock is still down by
  6. Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    By Lisa Levin Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. FaZe Holdings Inc. (NASDAQ: FAZE ) gained 46.9% to $0.2247 after falling over 4% on Friday. Av